Connect with us

Published

on

When the Covid pandemic had many Americans declining to go to the grocery store in 2020, sales at online grocery startup Instacart rose 590%, and its venture capital valuation soared to $39 billion. As the San Francisco company prepares to go public this week, the world has changed. And so has Instacart and its deal.

In a twist for an internet-oriented retailer, Instacart’s enterprise valuation in its initial public offering isn’t outlandish: It’s as little as 15 times earnings before interest, taxes, depreciation and amortization charges for the 12 months that ended in June. At the top of the latest IPO price range, the enterprise value would be 16x EBITDA. And in another twist for a sector where the most-common IPO candidates are newly or barely profitable, but growing so rapidly that large profits look imminent, the company will need to rekindle sales growth after a lull in the first half of this year, its first slowdown since the Covid pandemic, Renaissance Capital analyst Matt Einhorn said, whose firm focuses on IPO research and runs an IPO-focused exchange-traded fund.

“They haven’t done anything wrong,” Einhorn said. “That was just a different time.”

For investors, the good news is that Instacart got much bigger during the pandemic, and its profitability is inflecting higher now. The better news may be that its valuation skyrocketed before a private financing that valued the company at a reported $39 billion in 2021 – and then sank as Covid fever waned.

There is some sign that Instacart’s IPO pitch may be working. On Friday, the company raised the price target for its deal by $2 a share, or 7.4% at the midpoint of the old and new price ranges, with Instacart now seeking a value up to $10 billion, according to its latest IPO prospectus update, and a plan to sell shares at $28 to $30 apiece, giving public investors a better shot at a profit. With roughly $2 billion in cash on the balance sheet, the company’s enterprise value would be as high as $8 billion at the top of its IPO range. 

It isn’t the only planned tech IPO of the week to now see some room to up its valuation range, with marketing automation company Klaviyo doing the same.

Low valuation defuses the risk that burned investors in DoorDash, a different Web-fueled food delivery business that went public in December 2020. DoorDash shares closed at $189.51 on their first day of trading, surged to nearly $250, and are now a bit above $80. 

Doordash is a good place to start in evaluating Instacart, according to Einhorn. 

Indeed, the numbers say Instacart is a lot like DoorDash, but at a fraction of the price.

DoorDash, which mostly delivers restaurant meals, posted a net loss in the first half of this year on sales of $4.17 billion, but made $687 million in EBITDA over the prior 12 months, according to its second-quarter report. At today’s stock price, Doordash is worth about $32 billion, about 37 times its EBITDA for the 12 months that ended in June and 21 times its 2024 EBITDA, as estimated by ISI Evercore analyst Mark Mahaney. 

Instacart, on the other hand, has generated $486 million in EBITDA in the last year, including $279 million in the last six months, reversing a $20 million EBITDA loss in early 2022 as economies of scale kick in. Almost three-fourths of revenue comes from transaction fees of about $16 an order, split between the store and the customer, and about 28% comes from advertising. And the company is asking for a valuation less than one-third as high as DoorDash’s, and about a tenth of what DoorDash commanded at its peak.

Instacart’s pitch is that online sales are only 12% of the $1.1 trillion Americans spend on groceries, mostly at stores like Walmart, Kroger and Aldi that are partners with Instacart. The company thinks that share can double, though its roadshow presentation doesn’t say exactly how soon. And, in a nod to growth worries, Instacart is also selling itself as a cash-conscious business that invests carefully, with an eye toward short-term returns, while building up its advertising business to keep building profit even as sales growth slows.

That reflects a hard-won skepticism about Web business models that had been powered by Covid-driven hypergrowth, Einhorn said.

“They won’t do 2020 growth again and probably will grow less than in 2021 and 2022,” he said. 

Industry sources are split on how fast Instacart will grow now, said Third Bridge analyst Nicholas Cauley. More aggressive experts consulted by the New York research firm think Instacart can boost gross sales by almost 20% this year and next, helped by market share gains that can be achieved with higher marketing spending after the IPO, he said. Relative pessimists think sales will grow by a high single-digit percentage.

“They have industry leading selection and the app is good for the user,” Cauley said. 

Indeed, the waning of Covid has tapped the brakes on Instacart’s growth  The company told analysts on its roadshow that the early part of this year was the first period when it did not think sales were inflated by Covid fears, either the original version or the less-intense recurrence driven by the Omicron variant in late 2021 and early 2022.

Gross sales grew just 3% in the first quarter and 6% in the second three months of 2023, down from the 18% average the company posted in 2021 and 2022.  Instacart’s revenue grew 31% in the first half of 2023, however, as it added high-margin advertising sales and other income.

The right valuation for Instacart depends on where the ultimate rate of sales growth falls, Einhorn said. 

In its roadshow presentation, which the company has made public, Instacart projects that its long-term business model will capture between 6.5% and 7.5% of each dollar a consumer spends in service charges and other revenue to Instacart (the rest is passed through to grocery stores who sell on the platform). Another 4% to 5% of gross sales will flow to Instacart in the form of advertising revenue, mostly from consumer products companies.

The company’s plans turn on getting loyal customers who belong to the company’s Instacart+ program, a $99 a year subscription plan that gives free grocery delivery and cash back on some orders, Instacart chief financial officer Nick Giovanni said in the investor presentation. He acknowledges that customers who began shopping at Instacart during Covid have been less loyal than earlier adopters, but said sales to new customers this year are 60% higher than in pre-Covid 2019.

“We expect to see some headwinds,” he said.  

Instacart+ may be the key to the future, according to Cauley. Members shop more often and spend more each time, and larger orders are more profitable because they use workers’ time more efficiently and require less marketing spend. 

“Once customers get on the platform, they tend to be sticky,” he said.

The company’s pitch turns on its ability to boost profits by containing costs as sales grow more slowly. Since its store partners buy and sell the food themselves, Instagram’s cost of goods is about the cost of running its Instacart.com platform, which is essentially a locally tailored marketplace of supermarkets that are its partners, and private-label store sites; and of delivering packages to consumers. 

The company says those costs will dip to just 22% of revenue, from 28% last year and 25% early this year, as it moves toward its “long-term target” levels. Its capital spending is very low, and its corporate overhead and marketing were 53% of revenue in early 2023.  The company believes it can double its EBITDA as a percentage of sales to 39%, according to its presentation.

“When a customer orders more than 20 items, everything about the process is different,” Giovanni said.

Instacart’s prospectus cites market research firm Incisiv as saying the online grocery market will grow between 10% and 18% annually through 2025. If Instacart regains sales growth of 18%, that would work out to 2025 revenue of $5.9 billion, gross profit of $4.63 billion, and EBITDA of $2.3 billion. Including the cash on the company’s balance sheet, that values Instacart at about three times EBITDA – way below DoorDash’s valuation.

At 10% growth in merchandise sales, which Einhorn thinks is closer to the mark, Instacart’s share of that revenue climbs to as much as $2.88 billion in 2025, with EBITDA of about $1.12 billion. Even that would value the company at only seven times 2025 EBITDA, and about 14 times EBITDA from the last four quarters, still a sharp discount to DoorDash. Grocery giant Kroger trades at 13 times net income.

So in a twist few would have predicted in 2020 or 2021, Instacart is trying to go public as a value stock, carefully managed to wring the best results from potentially modest growth. Investors will soon show whether they are buying.

Continue Reading

Technology

Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million

Published

on

By

Anne Wojcicki has a new offer to take 23andMe private, this time for .7 million

Anne Wojcicki attends the WSJ Magazine Style & Tech Dinner in Atherton, California, on March 15, 2023.

Kelly Sullivan | Getty Images Entertainment | Getty Images

23andMe CEO Anne Wojcicki and New Mountain Capital have submitted a proposal to take the embattled genetic testing company private, according to a Friday filing with the U.S. Securities and Exchange Commission.

Wojcicki and New Mountain have offered to acquire all of 23andMe’s outstanding shares in cash for $2.53 per share, or an equity value of approximately $74.7 million. The company’s stock closed at $2.42 on Friday with a market cap of about $65 million.

The offer comes after a turbulent year for 23andMe, with the stock losing more than 80% of its value in 2024. In January, the company announced plans to explore strategic alternatives, which could include a sale of the company or its assets, a restructuring or a business combination. 

Read more CNBC tech news

23andMe has a special committee of independent directors in place to evaluate potential paths forward. The company appointed three new independent directors to its board in October after all seven of its previous directors abruptly resigned the prior month. The special committee has to approve Wojcicki and New Mountain’s proposal.

“We believe that our Proposal provides compelling value and immediate liquidity to the Company’s public stockholders,” Wojcicki and Matthew Holt, managing director and president of private equity at New Mountain, wrote in a letter to the special committee on Thursday.

Wojcicki previously submitted a proposal to take the company private for 40 cents per share in July, but it was rejected by the special committee, in part because the members said it lacked committed financing and did not provide a premium to the closing price at the time.

Wojcicki and New Mountain are willing to provide secured debt financing to fund 23andMe’s operations through the transaction’s closing, the filing said. New Mountain is based in New York and has $55 billion of assets under management, according to its website.

23andMe declined to comment.

WATCH: The rise and fall of 23andMe

The rise and fall of 23andMe

Continue Reading

Technology

Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

Published

on

By

Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage

Hims & Hers

Shares of Hims & Hers Health tumbled more than 23% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved.

Semaglutide is the active ingredient in Novo Nordisk‘s blockbuster weight loss drug Wegovy and diabetes treatment Ozempic. Those medications are part of a class of drugs called GLP-1s, and demand for the treatments has exploded in recent years. As a result, digital health companies such as Hims & Hers have been prescribing compounded semaglutide as an alternative for patients who are navigating volatile supply hurdles and insurance obstacles.

Compounded drugs are custom-made alternatives to brand-name drugs designed to meet a specific patient’s needs, and compounders are allowed to produce them when brand-name treatments are in shortage. The FDA doesn’t review the safety and efficacy of compounded products.

Hims & Hers began offering compounded semaglutide to patients in May, and it owns compounding pharmacies that produce the medications.

Compounded medications are typically much cheaper than their branded counterparts. Hims & Hers sells compounded semaglutide for less than $200 per month, while Ozempic and Wegovy both cost around $1,000 per month without insurance.

Read more CNBC tech news

The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days, depending on the type of facility, in order to “avoid unnecessary disruption to patient treatment.”

“Now that the FDA has determined the drug shortage for semaglutide has been resolved, we will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO Andrew Dudum posted Friday on X. “We’re also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have ‘capacity limitations’ and ‘expected continued periodic supply constraints and related drug shortage notifications.'”

Him & Hers’ weight loss offerings have been a massive hit with investors. Shares of the company climbed more than 200% last year, and the stock is already up more than 100% this year despite Friday’s move.

Even before it added compounded GLP-1s to its portfolio, the company said in its 2023 fourth-quarter earnings call that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025.

Despite the turbulent regulatory landscape, Hims & Hers has showed no signs of slowing down.

On Friday, the company announced it has acquired a U.S.-based peptide facility that will “further verticalize the company’s long-term ability to deliver personalized medications.” Hims & Hers will explore advances across metabolic optimization, recovery science, biological resistances, cognitive performance and preventative health through the acquisition, the company said.

That move comes just days after Hims & Hers also bought Trybe Labs, the New Jersey-based at-home lab testing facility. Trybe Labs will allow Hims & Hers to perform at-home blood draws and more comprehensive pretreatment testing.

Hims & Hers did not disclose the terms of either deal.

WATCH: Hims & Hers Super Bowl ad sparks controversy

Hims & Hers Super Bowl ad sparks controversy

Continue Reading

Technology

Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems

Published

on

By

Tesla recalls more than 375,000 vehicles in U.S. due to failing power-assisted steering systems

Tesla models Y and 3 are displayed at a Tesla dealership in Corte Madera, California, on Dec. 20, 2024.

Justin Sullivan | Getty Images

Tesla is voluntarily recalling 376,241vehicles in the U.S. to correct an issue with failing power-assisted steering systems, according to records posted to the website of the U.S. National Highway Traffic Safety Administration.

In a safety recall report posted on the NHTSA website, Tesla said the recall includes Model 3 and Model Y vehicles that were manufactured for sale in the U.S. from Feb. 28, 2023, to October 11, 2023, and that were equipped with a certain older software release.

The records said printed circuit boards in the steering systems in affected vehicles could become overstressed, causing the power-assist steering to fail in some cases when a Tesla vehicle rolled to a stop and then accelerated.

When electronic power-assist steering systems fail in a Tesla, drivers need to exert more force to steer their cars, which can increase the risk of a collision.

Read more CNBC tech news

Tesla told the vehicle safety regulator that it was not aware of any crashes, injuries or deaths related to the power steering failures, and that it was offering an over-the-air software update as a remedy.

The recall follows an earlier related probe and voluntary recall in China concerning the same systems.

President Donald Trump has appointed Tesla CEO Elon Musk to lead a team that is slashing the federal government workforce, and in some cases, regulations and entire agencies. Those cuts already affected the NHTSA, an agency Musk has long seen as standing in the way of some of his ambitions at Tesla.

The regulator has been engaged in a yearslong investigation into safety defects in the systems that Tesla markets currently as its Autopilot and Full Self-Driving (Supervised) options. The features do not make Tesla cars into robotaxis. They require a human driver ready to steer or brake at any time.

The Washington Post reported on Thursday that Musk’s team has led mass firings at the NHTSA, reducing the agency’s workforce and capacity to investigate companies including Tesla by about 10%.

Tesla didn’t respond to a request for comment.

WATCH: Tesla stock hinges on new vehicles being introduced

Tesla stock hinges on new vehicles being introduced, says Canaccord's  George Gianarikas

Continue Reading

Trending